Skip to content
Menu

Barclays Maintains Overweight on Phathom Pharmaceuticals, Lowers Price Target to $10

Benzinga Newsdesk 18 hours ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Barclays analyst Glen Santangelo maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Overweight and lowers the price target from $14 to $10.

Barclays analyst Glen Santangelo maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Overweight and lowers the price target from $14 to $10.

Read at benzinga.com